Bevacizumab, anlotinib, and etoposide for older or frail patients with small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as the first treatment for small-cell lung cancer that has spread. It is designed for older patients or those who cannot tolerate standard intensive chemotherapy, with the goal of controlling the cancer while being gentler on the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older, or you are 18 or older and your doctor says you are not fit for intensive chemotherapy.
- You have been diagnosed with small-cell lung cancer that has spread to other parts of the body.
- You have not had any prior treatment for this cancer, except if you had treatment for an earlier stage and it came back more than 6 months after finishing.
- You have at least one tumor that can be measured on a CT or MRI scan.
- Your overall health status is good enough (ECOG score of 0 to 3) and your organ function (like blood counts, liver, and kidneys) is within acceptable limits.
- You are willing to use effective contraception if you are of childbearing potential, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a new combination of an immunotherapy drug, a targeted therapy, and standard chemotherapy plus radiation for people with limited-stage small cell lung cancer. It aims to see if this combination improves outcomes compared to standard treatment alone.
This trial tests a combination of two medicines (etoposide and benmelstobart) followed by a maintenance treatment with benmelstobart and anlotinib for older adults with extensive-stage small cell lung cancer. The goal is to see if this treatment helps control the cancer and is safe for patients who may not tolerate standard platinum-based chemo.
This study tests a new combination therapy for extensive-stage small cell lung cancer (cancer that has spread beyond the lung). The treatment includes an immunotherapy drug, a drug that blocks blood vessel growth to tumors, and chemotherapy. It aims to see how well this combination works in people who have not yet been treated for this cancer.
Hear when a new Small Cell Lung Cancer ( SCLC ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.